Anteris Technologies achieves breakthrough in ADAPT® products to create consistently thin tissue The proven benefits of its ADAPT® tissue technology, paired with DurAVR™’s unique 3D single piece aortic valve design, have potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons. Anteris a structural heart company delivering clinically superior and durable solutions through better science and better design. Anteris Technologies Ltd (ASX:AVR) has achieved a breakthrough in manufacturing the tissue used in ADAPT® treated products from bovine pericardium, after developing specialised machinery to create consistently thin tissue through an innovative processing technique.